BRPI0617100A2 - composto derivado de piridazinona, composição farmacêutica, método para previnir ou tratar uma doença e uso de um composto derivado de piridazinona - Google Patents
composto derivado de piridazinona, composição farmacêutica, método para previnir ou tratar uma doença e uso de um composto derivado de piridazinona Download PDFInfo
- Publication number
- BRPI0617100A2 BRPI0617100A2 BRPI0617100-1A BRPI0617100A BRPI0617100A2 BR PI0617100 A2 BRPI0617100 A2 BR PI0617100A2 BR PI0617100 A BRPI0617100 A BR PI0617100A BR PI0617100 A2 BRPI0617100 A2 BR PI0617100A2
- Authority
- BR
- Brazil
- Prior art keywords
- substituted
- unsubstituted
- methylphenyl
- hydrogen
- alkyl
- Prior art date
Links
- -1 pyridazinone derivative compound Chemical class 0.000 title claims abstract description 325
- 238000000034 method Methods 0.000 title claims abstract description 28
- 201000010099 disease Diseases 0.000 title claims abstract description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 10
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 10
- 239000001257 hydrogen Substances 0.000 claims abstract description 101
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 101
- 150000002431 hydrogen Chemical class 0.000 claims abstract description 63
- 150000001875 compounds Chemical class 0.000 claims abstract description 50
- AAILEWXSEQLMNI-UHFFFAOYSA-N 1h-pyridazin-6-one Chemical compound OC1=CC=CN=N1 AAILEWXSEQLMNI-UHFFFAOYSA-N 0.000 claims abstract description 40
- 150000003839 salts Chemical class 0.000 claims abstract description 36
- 229910052760 oxygen Inorganic materials 0.000 claims abstract description 16
- 239000001301 oxygen Substances 0.000 claims abstract description 16
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims abstract description 15
- 125000000217 alkyl group Chemical group 0.000 claims description 155
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims description 107
- 125000001424 substituent group Chemical group 0.000 claims description 74
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 69
- 125000003545 alkoxy group Chemical group 0.000 claims description 57
- 229910052736 halogen Inorganic materials 0.000 claims description 44
- 150000002367 halogens Chemical group 0.000 claims description 44
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 38
- 125000003118 aryl group Chemical group 0.000 claims description 37
- 125000002947 alkylene group Chemical group 0.000 claims description 36
- 125000004215 2,4-difluorophenyl group Chemical group [H]C1=C([H])C(*)=C(F)C([H])=C1F 0.000 claims description 34
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 34
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 34
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims description 29
- 125000001589 carboacyl group Chemical group 0.000 claims description 28
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims description 25
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 25
- 125000001118 alkylidene group Chemical group 0.000 claims description 21
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 21
- 125000004423 acyloxy group Chemical group 0.000 claims description 19
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 19
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 17
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 16
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 16
- 125000005842 heteroatom Chemical group 0.000 claims description 16
- DXASQZJWWGZNSF-UHFFFAOYSA-N n,n-dimethylmethanamine;sulfur trioxide Chemical group CN(C)C.O=S(=O)=O DXASQZJWWGZNSF-UHFFFAOYSA-N 0.000 claims description 14
- 125000004432 carbon atom Chemical group C* 0.000 claims description 12
- 125000005915 C6-C14 aryl group Chemical group 0.000 claims description 10
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims description 9
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 7
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 7
- SUDIDDCAFMIBIF-UHFFFAOYSA-N 6-[2-(4-fluorophenyl)-6,6-dimethyl-5,7-dihydro-4H-pyrazolo[1,5-a]pyrimidin-3-yl]-2-(2-methylphenyl)pyridazin-3-one Chemical compound CC1=C(C=CC=C1)N1N=C(C=CC1=O)C1=C2NCC(C)(C)CN2N=C1C1=CC=C(F)C=C1 SUDIDDCAFMIBIF-UHFFFAOYSA-N 0.000 claims description 6
- 208000011231 Crohn disease Diseases 0.000 claims description 6
- 206010061218 Inflammation Diseases 0.000 claims description 6
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 6
- 201000004681 Psoriasis Diseases 0.000 claims description 6
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 6
- 230000004054 inflammatory process Effects 0.000 claims description 6
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims description 6
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 claims description 5
- 125000001072 heteroaryl group Chemical group 0.000 claims description 5
- 230000002265 prevention Effects 0.000 claims description 5
- 241000124008 Mammalia Species 0.000 claims description 4
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims description 4
- 125000004750 (C1-C6) alkylaminosulfonyl group Chemical group 0.000 claims description 3
- 125000005947 C1-C6 alkylsulfonyloxy group Chemical group 0.000 claims description 2
- 125000005708 carbonyloxy group Chemical group [*:2]OC([*:1])=O 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 125000001544 thienyl group Chemical group 0.000 claims description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 14
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 claims 1
- QXYRMVUWXFWUKP-UHFFFAOYSA-N 6-[2-(4-fluorophenyl)-6-hydroxy-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidin-3-yl]-2-(2-methylphenyl)pyridazin-3-one Chemical compound CC1=CC=CC=C1N1C(=O)C=CC(C=2C(=NN3CC(O)CNC3=2)C=2C=CC(F)=CC=2)=N1 QXYRMVUWXFWUKP-UHFFFAOYSA-N 0.000 claims 1
- 125000000547 substituted alkyl group Chemical group 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 10
- 125000003107 substituted aryl group Chemical group 0.000 abstract description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 260
- 238000005160 1H NMR spectroscopy Methods 0.000 description 177
- 239000000203 mixture Substances 0.000 description 112
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 101
- 238000002360 preparation method Methods 0.000 description 73
- 239000000243 solution Substances 0.000 description 72
- 125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 description 69
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 62
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 58
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 51
- HEDRZPFGACZZDS-UHFFFAOYSA-N chloroform Substances ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 47
- 235000019439 ethyl acetate Nutrition 0.000 description 47
- 239000011734 sodium Substances 0.000 description 43
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 42
- 239000007787 solid Substances 0.000 description 36
- 239000012044 organic layer Substances 0.000 description 32
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 30
- 239000012267 brine Substances 0.000 description 28
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 28
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 27
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 27
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 26
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 26
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 24
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 24
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 20
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 19
- 239000011737 fluorine Substances 0.000 description 19
- 229910052731 fluorine Inorganic materials 0.000 description 19
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 18
- 238000004440 column chromatography Methods 0.000 description 18
- 239000000725 suspension Substances 0.000 description 18
- 239000003480 eluent Substances 0.000 description 17
- 125000003944 tolyl group Chemical group 0.000 description 17
- 125000000040 m-tolyl group Chemical group [H]C1=C([H])C(*)=C([H])C(=C1[H])C([H])([H])[H] 0.000 description 16
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- 239000000460 chlorine Substances 0.000 description 15
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 14
- 229920006395 saturated elastomer Polymers 0.000 description 14
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 13
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical class CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 13
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 13
- 229910052794 bromium Inorganic materials 0.000 description 13
- 229910052801 chlorine Inorganic materials 0.000 description 13
- 239000000706 filtrate Substances 0.000 description 13
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 13
- 235000019341 magnesium sulphate Nutrition 0.000 description 13
- 238000010828 elution Methods 0.000 description 12
- 239000000284 extract Substances 0.000 description 12
- 238000003818 flash chromatography Methods 0.000 description 12
- 239000011541 reaction mixture Substances 0.000 description 12
- 238000003756 stirring Methods 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 12
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 11
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 11
- 239000003921 oil Substances 0.000 description 11
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 11
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 10
- 229910004298 SiO 2 Inorganic materials 0.000 description 10
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical class CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 10
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 10
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 9
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 9
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 9
- 239000000843 powder Substances 0.000 description 9
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 description 8
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 8
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 8
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 8
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 8
- ZIEWSZYVEDTXGH-UHFFFAOYSA-N pyrimidine-4-carbonitrile Chemical compound N#CC1=CC=NC=N1 ZIEWSZYVEDTXGH-UHFFFAOYSA-N 0.000 description 8
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 7
- 125000000753 cycloalkyl group Chemical group 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 239000011630 iodine Substances 0.000 description 7
- 229910052740 iodine Inorganic materials 0.000 description 7
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 6
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 6
- 229910052757 nitrogen Inorganic materials 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 125000006619 (C1-C6) dialkylamino group Chemical group 0.000 description 5
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 5
- IXFNXFDKORMOGG-UHFFFAOYSA-N 2-(2-methylphenyl)pyridazin-3-one Chemical compound CC1=CC=CC=C1N1C(=O)C=CC=N1 IXFNXFDKORMOGG-UHFFFAOYSA-N 0.000 description 5
- LYHNSWOZRDSWLX-UHFFFAOYSA-N 6-[2-(4-fluorophenyl)-6-(hydroxymethyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidin-3-yl]-2-(2-methylphenyl)pyridazin-3-one Chemical compound CC1=CC=CC=C1N1C(=O)C=CC(C=2C(=NN3CC(CO)CNC3=2)C=2C=CC(F)=CC=2)=N1 LYHNSWOZRDSWLX-UHFFFAOYSA-N 0.000 description 5
- 102000004127 Cytokines Human genes 0.000 description 5
- 108090000695 Cytokines Proteins 0.000 description 5
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical group CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 5
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 5
- 206010036030 Polyarthritis Diseases 0.000 description 5
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical compound CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 5
- 102100040247 Tumor necrosis factor Human genes 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 125000002393 azetidinyl group Chemical group 0.000 description 5
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 5
- 125000005935 hexyloxycarbonyl group Chemical group 0.000 description 5
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 5
- 125000002757 morpholinyl group Chemical group 0.000 description 5
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 5
- 125000001148 pentyloxycarbonyl group Chemical group 0.000 description 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 5
- 125000004353 pyrazol-1-yl group Chemical group [H]C1=NN(*)C([H])=C1[H] 0.000 description 5
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 5
- 125000004943 pyrimidin-6-yl group Chemical group N1=CN=CC=C1* 0.000 description 5
- YPOXGDJGKBXRFP-UHFFFAOYSA-N pyrimidine-4-carboxylic acid Chemical compound OC(=O)C1=CC=NC=N1 YPOXGDJGKBXRFP-UHFFFAOYSA-N 0.000 description 5
- RUPAXCPQAAOIPB-UHFFFAOYSA-N tert-butyl formate Chemical group CC(C)(C)OC=O RUPAXCPQAAOIPB-UHFFFAOYSA-N 0.000 description 5
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 4
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 4
- KTPOXQVGTABKFF-UHFFFAOYSA-N 6-[2-(2,4-difluorophenyl)-6-(hydroxymethyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidin-3-yl]-2-(2-methylphenyl)pyridazin-3-one Chemical compound CC1=CC=CC=C1N1C(=O)C=CC(C=2C(=NN3CC(CO)CNC3=2)C=2C(=CC(F)=CC=2)F)=N1 KTPOXQVGTABKFF-UHFFFAOYSA-N 0.000 description 4
- 101000977207 Drosophila melanogaster Mitogen-activated protein kinase p38a Proteins 0.000 description 4
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- OPQARKPSCNTWTJ-UHFFFAOYSA-L copper(ii) acetate Chemical compound [Cu+2].CC([O-])=O.CC([O-])=O OPQARKPSCNTWTJ-UHFFFAOYSA-L 0.000 description 4
- 125000001664 diethylamino group Chemical group [H]C([H])([H])C([H])([H])N(*)C([H])([H])C([H])([H])[H] 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 4
- 210000000548 hind-foot Anatomy 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 239000010410 layer Substances 0.000 description 4
- 125000005476 oxopyrrolidinyl group Chemical group 0.000 description 4
- 125000004944 pyrazin-3-yl group Chemical group [H]C1=C([H])N=C(*)C([H])=N1 0.000 description 4
- OKULHRWWYCFJAB-UHFFFAOYSA-N pyrimidine-4-carbaldehyde Chemical compound O=CC1=CC=NC=N1 OKULHRWWYCFJAB-UHFFFAOYSA-N 0.000 description 4
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 4
- 238000010898 silica gel chromatography Methods 0.000 description 4
- 235000017557 sodium bicarbonate Nutrition 0.000 description 4
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 4
- 125000004434 sulfur atom Chemical group 0.000 description 4
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
- FOQHPFUEEKPISH-UHFFFAOYSA-N 2-(6-chloropyridazin-3-yl)-1-(4-fluorophenyl)ethanone Chemical compound C1=CC(F)=CC=C1C(=O)CC1=CC=C(Cl)N=N1 FOQHPFUEEKPISH-UHFFFAOYSA-N 0.000 description 3
- 125000004195 4-methylpiperazin-1-yl group Chemical group [H]C([H])([H])N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 description 3
- KDWXNVQYEFVHPZ-UHFFFAOYSA-N 6-[2-(2,4-difluorophenyl)-6-[(dimethylamino)methyl]-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidin-3-yl]-2-(2-methylphenyl)pyridazin-3-one Chemical compound N=1N2CC(CN(C)C)CNC2=C(C2=NN(C(=O)C=C2)C=2C(=CC=CC=2)C)C=1C1=CC=C(F)C=C1F KDWXNVQYEFVHPZ-UHFFFAOYSA-N 0.000 description 3
- LBEHXJNZFUBWGR-UHFFFAOYSA-N 6-[2-(4-fluorophenyl)-2-oxoethyl]-2-(2-methylphenyl)pyridazin-3-one Chemical compound CC1=CC=CC=C1N1C(=O)C=CC(CC(=O)C=2C=CC(F)=CC=2)=N1 LBEHXJNZFUBWGR-UHFFFAOYSA-N 0.000 description 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 238000005481 NMR spectroscopy Methods 0.000 description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 3
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 229960000583 acetic acid Drugs 0.000 description 3
- 230000000202 analgesic effect Effects 0.000 description 3
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 3
- 239000004305 biphenyl Substances 0.000 description 3
- 235000010290 biphenyl Nutrition 0.000 description 3
- 235000011089 carbon dioxide Nutrition 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000016396 cytokine production Effects 0.000 description 3
- FAMRKDQNMBBFBR-BQYQJAHWSA-N diethyl azodicarboxylate Substances CCOC(=O)\N=N\C(=O)OCC FAMRKDQNMBBFBR-BQYQJAHWSA-N 0.000 description 3
- 125000006222 dimethylaminomethyl group Chemical group [H]C([H])([H])N(C([H])([H])[H])C([H])([H])* 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N dimethylformamide Substances CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 239000002158 endotoxin Substances 0.000 description 3
- FAMRKDQNMBBFBR-UHFFFAOYSA-N ethyl n-ethoxycarbonyliminocarbamate Chemical compound CCOC(=O)N=NC(=O)OCC FAMRKDQNMBBFBR-UHFFFAOYSA-N 0.000 description 3
- 125000005843 halogen group Chemical group 0.000 description 3
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 239000002198 insoluble material Substances 0.000 description 3
- 238000007918 intramuscular administration Methods 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 3
- 229920006008 lipopolysaccharide Polymers 0.000 description 3
- 125000006533 methyl amino methyl group Chemical group [H]N(C([H])([H])[H])C([H])([H])* 0.000 description 3
- 239000012046 mixed solvent Substances 0.000 description 3
- 150000002923 oximes Chemical class 0.000 description 3
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N phenylbenzene Natural products C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 3
- 125000004742 propyloxycarbonyl group Chemical group 0.000 description 3
- HKSQZEGSMBFHGC-UHFFFAOYSA-N pyrimidine-4-carboxamide Chemical compound NC(=O)C1=CC=NC=N1 HKSQZEGSMBFHGC-UHFFFAOYSA-N 0.000 description 3
- 229910052717 sulfur Inorganic materials 0.000 description 3
- 239000011593 sulfur Substances 0.000 description 3
- WITMXBRCQWOZPX-UHFFFAOYSA-N 1-phenylpyrazole Chemical compound C1=CC=NN1C1=CC=CC=C1 WITMXBRCQWOZPX-UHFFFAOYSA-N 0.000 description 2
- KXYBVKOGKCSFFI-UHFFFAOYSA-N 3-[(dimethylamino)methyl]azetidine-1-carbothiohydrazide Chemical compound CN(C)CC1CN(C(=S)NN)C1 KXYBVKOGKCSFFI-UHFFFAOYSA-N 0.000 description 2
- GSGOGCKGCIAYLL-UHFFFAOYSA-N 3-[2-(4-fluorophenyl)-2-oxoethyl]-1h-pyridazin-6-one Chemical compound C1=CC(F)=CC=C1C(=O)CC1=NNC(=O)C=C1 GSGOGCKGCIAYLL-UHFFFAOYSA-N 0.000 description 2
- AVLRPQBKZSYLED-UHFFFAOYSA-N 3-[6-(4-fluorophenyl)-7-[1-(2-methylphenyl)-6-oxopyridazin-3-yl]-2,3-dihydroimidazo[1,2-b]pyrazol-1-yl]propanoic acid Chemical compound CC1=CC=CC=C1N1C(=O)C=CC(C2=C3N(CCC(O)=O)CCN3N=C2C=2C=CC(F)=CC=2)=N1 AVLRPQBKZSYLED-UHFFFAOYSA-N 0.000 description 2
- HLKONDFQQHNQJK-UHFFFAOYSA-N 3-[[2-(2,4-difluorophenyl)-1,3-dioxolan-2-yl]methyl]-1h-pyridazin-6-one Chemical compound FC1=CC(F)=CC=C1C1(CC2=NNC(=O)C=C2)OCCO1 HLKONDFQQHNQJK-UHFFFAOYSA-N 0.000 description 2
- AHARRJLATDBVBU-UHFFFAOYSA-N 3-[[2-(4-fluorophenyl)-1,3-dioxolan-2-yl]methyl]-1h-pyridazin-6-one Chemical compound C1=CC(F)=CC=C1C1(CC2=NNC(=O)C=C2)OCCO1 AHARRJLATDBVBU-UHFFFAOYSA-N 0.000 description 2
- QOXOZONBQWIKDA-UHFFFAOYSA-N 3-hydroxypropyl Chemical group [CH2]CCO QOXOZONBQWIKDA-UHFFFAOYSA-N 0.000 description 2
- UQGCZJUCUGZCKD-DEOSSOPVSA-N 6-[(6S)-2-(4-fluorophenyl)-6-phenylmethoxy-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidin-3-yl]-2-(2-methylphenyl)pyridazin-3-one Chemical compound CC1=CC=CC=C1N1C(=O)C=CC(C=2C(=NN3C[C@H](CNC3=2)OCC=2C=CC=CC=2)C=2C=CC(F)=CC=2)=N1 UQGCZJUCUGZCKD-DEOSSOPVSA-N 0.000 description 2
- WXIZSONXZNJOLJ-UHFFFAOYSA-N 6-[1-bromo-2-(2,4-difluorophenyl)-2-oxoethyl]-2-(2-methylphenyl)pyridazin-3-one Chemical compound CC1=CC=CC=C1N1C(=O)C=CC(C(Br)C(=O)C=2C(=CC(F)=CC=2)F)=N1 WXIZSONXZNJOLJ-UHFFFAOYSA-N 0.000 description 2
- JBAZSHKDGSLFQS-UHFFFAOYSA-N 6-[2-(2,4-difluorophenyl)-6-(methylaminomethyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidin-3-yl]-2-(2-methylphenyl)pyridazin-3-one Chemical compound N=1N2CC(CNC)CNC2=C(C2=NN(C(=O)C=C2)C=2C(=CC=CC=2)C)C=1C1=CC=C(F)C=C1F JBAZSHKDGSLFQS-UHFFFAOYSA-N 0.000 description 2
- LYABFVJNJUUFLU-UHFFFAOYSA-N 6-[2-(2,5-difluorophenyl)-6-(methylaminomethyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidin-3-yl]-2-(2-methylphenyl)pyridazin-3-one Chemical compound N=1N2CC(CNC)CNC2=C(C2=NN(C(=O)C=C2)C=2C(=CC=CC=2)C)C=1C1=CC(F)=CC=C1F LYABFVJNJUUFLU-UHFFFAOYSA-N 0.000 description 2
- FTCKGEIDCRJVCG-UHFFFAOYSA-N 6-[2-(2,5-difluorophenyl)-6-[(dimethylamino)methyl]-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidin-3-yl]-2-(2-methylphenyl)pyridazin-3-one Chemical compound N=1N2CC(CN(C)C)CNC2=C(C2=NN(C(=O)C=C2)C=2C(=CC=CC=2)C)C=1C1=CC(F)=CC=C1F FTCKGEIDCRJVCG-UHFFFAOYSA-N 0.000 description 2
- IPLSOSBOJYAVCM-UHFFFAOYSA-N 6-[2-(2-chloro-4-fluorophenyl)-6-(diethylaminomethyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidin-3-yl]-2-(2-methylphenyl)pyridazin-3-one Chemical compound N=1N2CC(CN(CC)CC)CNC2=C(C2=NN(C(=O)C=C2)C=2C(=CC=CC=2)C)C=1C1=CC=C(F)C=C1Cl IPLSOSBOJYAVCM-UHFFFAOYSA-N 0.000 description 2
- INIHMYQXDIQSQR-UHFFFAOYSA-N 6-[2-(2-chloro-4-fluorophenyl)-6-(methylaminomethyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidin-3-yl]-2-(2-methylphenyl)pyridazin-3-one Chemical compound N=1N2CC(CNC)CNC2=C(C2=NN(C(=O)C=C2)C=2C(=CC=CC=2)C)C=1C1=CC=C(F)C=C1Cl INIHMYQXDIQSQR-UHFFFAOYSA-N 0.000 description 2
- AFFATFHXRWSSHY-UHFFFAOYSA-N 6-[2-(2-chloro-4-fluorophenyl)-6-[(dimethylamino)methyl]-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidin-3-yl]-2-(2-methylphenyl)pyridazin-3-one Chemical compound N=1N2CC(CN(C)C)CNC2=C(C2=NN(C(=O)C=C2)C=2C(=CC=CC=2)C)C=1C1=CC=C(F)C=C1Cl AFFATFHXRWSSHY-UHFFFAOYSA-N 0.000 description 2
- JCGYGSHDCKRRGT-UHFFFAOYSA-N 6-[2-(4-fluorophenyl)-6-methylidene-5,7-dihydro-4H-pyrazolo[1,5-a]pyrimidin-3-yl]-2-(2-methylphenyl)pyridazin-3-one Chemical compound CC1=CC=CC=C1N1C(=O)C=CC(C=2C(=NN3CC(=C)CNC3=2)C=2C=CC(F)=CC=2)=N1 JCGYGSHDCKRRGT-UHFFFAOYSA-N 0.000 description 2
- JCHYVBUYIWCCGT-UHFFFAOYSA-N 6-[3-(4-fluorophenyl)-5-oxo-1,2-dihydropyrazol-4-yl]-2-(2-methylphenyl)pyridazin-3-one Chemical compound CC1=CC=CC=C1N1C(=O)C=CC(C=2C(=NNC=2O)C=2C=CC(F)=CC=2)=N1 JCHYVBUYIWCCGT-UHFFFAOYSA-N 0.000 description 2
- IQZNYFHAHXQWME-UHFFFAOYSA-N 6-[5-(4-fluorophenyl)-3-[[4-(hydroxymethyl)thian-4-yl]methylamino]-1H-pyrazol-4-yl]-2-(2-methylphenyl)pyridazin-3-one Chemical compound CC1=CC=CC=C1N1C(=O)C=CC(C=2C(=NNC=2NCC2(CO)CCSCC2)C=2C=CC(F)=CC=2)=N1 IQZNYFHAHXQWME-UHFFFAOYSA-N 0.000 description 2
- FKNLIZZEDALVSZ-UHFFFAOYSA-N 6-[5-(ethylamino)-3-(4-fluorophenyl)-1-(2-hydroxyethyl)pyrazol-4-yl]-2-(2-methylphenyl)pyridazin-3-one Chemical compound N=1N(CCO)C(NCC)=C(C2=NN(C(=O)C=C2)C=2C(=CC=CC=2)C)C=1C1=CC=C(F)C=C1 FKNLIZZEDALVSZ-UHFFFAOYSA-N 0.000 description 2
- PXBBRPASPKYEGW-UHFFFAOYSA-N 6-[6-(diethylaminomethyl)-2-(2,4-difluorophenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidin-3-yl]-2-(2-methylphenyl)pyridazin-3-one Chemical compound N=1N2CC(CN(CC)CC)CNC2=C(C2=NN(C(=O)C=C2)C=2C(=CC=CC=2)C)C=1C1=CC=C(F)C=C1F PXBBRPASPKYEGW-UHFFFAOYSA-N 0.000 description 2
- SZNAGKHHHFYNLR-UHFFFAOYSA-N 6-[6-[(dimethylamino)methyl]-2-(3-methylphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidin-3-yl]-2-(2-methylphenyl)pyridazin-3-one Chemical compound N=1N2CC(CN(C)C)CNC2=C(C2=NN(C(=O)C=C2)C=2C(=CC=CC=2)C)C=1C1=CC=CC(C)=C1 SZNAGKHHHFYNLR-UHFFFAOYSA-N 0.000 description 2
- QVDATXLABOZANN-UHFFFAOYSA-N 6-[6-[(tert-butylamino)methyl]-2-(2,5-difluorophenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidin-3-yl]-2-(2-methylphenyl)pyridazin-3-one Chemical compound CC1=CC=CC=C1N1C(=O)C=CC(C=2C(=NN3CC(CNC(C)(C)C)CNC3=2)C=2C(=CC=C(F)C=2)F)=N1 QVDATXLABOZANN-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- 125000000041 C6-C10 aryl group Chemical group 0.000 description 2
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical group COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 2
- 208000009386 Experimental Arthritis Diseases 0.000 description 2
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 2
- 108091054455 MAP kinase family Proteins 0.000 description 2
- 102000043136 MAP kinase family Human genes 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- UFTDKYWOWFSRDR-UHFFFAOYSA-N [4-(aminomethyl)thian-4-yl]methanol Chemical compound NCC1(CO)CCSCC1 UFTDKYWOWFSRDR-UHFFFAOYSA-N 0.000 description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
- 125000002252 acyl group Chemical group 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 125000005279 aryl sulfonyloxy group Chemical group 0.000 description 2
- 125000004104 aryloxy group Chemical group 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- FFBHFFJDDLITSX-UHFFFAOYSA-N benzyl N-[2-hydroxy-4-(3-oxomorpholin-4-yl)phenyl]carbamate Chemical compound OC1=C(NC(=O)OCC2=CC=CC=C2)C=CC(=C1)N1CCOCC1=O FFBHFFJDDLITSX-UHFFFAOYSA-N 0.000 description 2
- 229960000074 biopharmaceutical Drugs 0.000 description 2
- 125000006309 butyl amino group Chemical group 0.000 description 2
- 125000004744 butyloxycarbonyl group Chemical group 0.000 description 2
- 125000001951 carbamoylamino group Chemical group C(N)(=O)N* 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 2
- 229910052681 coesite Inorganic materials 0.000 description 2
- 239000012230 colorless oil Substances 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- QTMDXZNDVAMKGV-UHFFFAOYSA-L copper(ii) bromide Chemical group [Cu+2].[Br-].[Br-] QTMDXZNDVAMKGV-UHFFFAOYSA-L 0.000 description 2
- 229910052906 cristobalite Inorganic materials 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 125000004772 dichloromethyl group Chemical group [H]C(Cl)(Cl)* 0.000 description 2
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 2
- VTXYBIGLJBVFOG-UHFFFAOYSA-N ethyl 3-(4-fluorophenyl)-2-[1-(2-methylphenyl)-6-oxopyridazin-3-yl]-3-oxopropanoate Chemical compound C1=CC(=O)N(C=2C(=CC=CC=2)C)N=C1C(C(=O)OCC)C(=O)C1=CC=C(F)C=C1 VTXYBIGLJBVFOG-UHFFFAOYSA-N 0.000 description 2
- FKRCODPIKNYEAC-UHFFFAOYSA-N ethyl propionate Chemical compound CCOC(=O)CC FKRCODPIKNYEAC-UHFFFAOYSA-N 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 229910052744 lithium Inorganic materials 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 229960000485 methotrexate Drugs 0.000 description 2
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 2
- UHOVQNZJYSORNB-UHFFFAOYSA-N monobenzene Natural products C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 2
- YFJAIURZMRJPDB-UHFFFAOYSA-N n,n-dimethylpiperidin-4-amine Chemical compound CN(C)C1CCNCC1 YFJAIURZMRJPDB-UHFFFAOYSA-N 0.000 description 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- NXJCBFBQEVOTOW-UHFFFAOYSA-L palladium(2+);dihydroxide Chemical compound O[Pd]O NXJCBFBQEVOTOW-UHFFFAOYSA-L 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 235000019260 propionic acid Nutrition 0.000 description 2
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 2
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- VTGOHKSTWXHQJK-UHFFFAOYSA-N pyrimidin-2-ol Chemical compound OC1=NC=CC=N1 VTGOHKSTWXHQJK-UHFFFAOYSA-N 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 235000012239 silicon dioxide Nutrition 0.000 description 2
- 125000004469 siloxy group Chemical group [SiH3]O* 0.000 description 2
- 239000012279 sodium borohydride Substances 0.000 description 2
- 229910000033 sodium borohydride Inorganic materials 0.000 description 2
- 125000003003 spiro group Chemical group 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 229910052682 stishovite Inorganic materials 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 230000026683 transduction Effects 0.000 description 2
- 238000010361 transduction Methods 0.000 description 2
- 229910052905 tridymite Inorganic materials 0.000 description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 2
- 230000006433 tumor necrosis factor production Effects 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- VCGRFBXVSFAGGA-UHFFFAOYSA-N (1,1-dioxo-1,4-thiazinan-4-yl)-[6-[[3-(4-fluorophenyl)-5-methyl-1,2-oxazol-4-yl]methoxy]pyridin-3-yl]methanone Chemical compound CC=1ON=C(C=2C=CC(F)=CC=2)C=1COC(N=C1)=CC=C1C(=O)N1CCS(=O)(=O)CC1 VCGRFBXVSFAGGA-UHFFFAOYSA-N 0.000 description 1
- NSJVYHOPHZMZPN-UHFFFAOYSA-N (2-methylphenyl)boronic acid Chemical compound CC1=CC=CC=C1B(O)O NSJVYHOPHZMZPN-UHFFFAOYSA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- 125000006708 (C5-C14) heteroaryl group Chemical group 0.000 description 1
- PAAZPARNPHGIKF-UHFFFAOYSA-N 1,2-dibromoethane Chemical compound BrCCBr PAAZPARNPHGIKF-UHFFFAOYSA-N 0.000 description 1
- ZVHHFWKWIVLISO-UHFFFAOYSA-N 1-(azetidin-3-yl)-n,n-dimethylmethanamine;dihydrochloride Chemical compound Cl.Cl.CN(C)CC1CNC1 ZVHHFWKWIVLISO-UHFFFAOYSA-N 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical group C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- ABDDQTDRAHXHOC-QMMMGPOBSA-N 1-[(7s)-5,7-dihydro-4h-thieno[2,3-c]pyran-7-yl]-n-methylmethanamine Chemical compound CNC[C@@H]1OCCC2=C1SC=C2 ABDDQTDRAHXHOC-QMMMGPOBSA-N 0.000 description 1
- SEZJHXMCHHSQJP-UHFFFAOYSA-N 1-amino-3-[[4-(hydroxymethyl)thian-4-yl]methyl]thiourea Chemical compound NNC(=S)NCC1(CO)CCSCC1 SEZJHXMCHHSQJP-UHFFFAOYSA-N 0.000 description 1
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 1
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
- HZNVUJQVZSTENZ-UHFFFAOYSA-N 2,3-dichloro-5,6-dicyano-1,4-benzoquinone Chemical compound ClC1=C(Cl)C(=O)C(C#N)=C(C#N)C1=O HZNVUJQVZSTENZ-UHFFFAOYSA-N 0.000 description 1
- NWOYAXCJZOCPIP-UHFFFAOYSA-N 2-(2-methylphenyl)-6-(2-phenyl-5-propan-2-yl-6,7-dihydro-4h-pyrazolo[1,5-a]pyrazin-3-yl)pyridazin-3-one Chemical compound C=12CN(C(C)C)CCN2N=C(C=2C=CC=CC=2)C=1C(=N1)C=CC(=O)N1C1=CC=CC=C1C NWOYAXCJZOCPIP-UHFFFAOYSA-N 0.000 description 1
- NBZURRLWUUNAJK-UHFFFAOYSA-N 2-(4-fluorophenyl)-3-[1-(2-methylphenyl)-6-oxopyridazin-3-yl]-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-6-carbonitrile Chemical compound CC1=CC=CC=C1N1C(=O)C=CC(C=2C(=NN3CC(CNC3=2)C#N)C=2C=CC(F)=CC=2)=N1 NBZURRLWUUNAJK-UHFFFAOYSA-N 0.000 description 1
- JIYWTGQPSWMLDJ-UHFFFAOYSA-N 2-(4-fluorophenyl)-3-[1-(2-methylphenyl)-6-oxopyridazin-3-yl]-5,7-dihydro-4H-pyrazolo[1,5-a]pyrimidin-6-one Chemical compound CC1=CC=CC=C1N1C(=O)C=CC(C=2C(=NN3CC(=O)CNC3=2)C=2C=CC(F)=CC=2)=N1 JIYWTGQPSWMLDJ-UHFFFAOYSA-N 0.000 description 1
- YSUHPFLFSFJJCO-UHFFFAOYSA-N 2-(6-chloropyridazin-3-yl)-1-(2,4-difluorophenyl)ethanone Chemical compound FC1=CC(F)=CC=C1C(=O)CC1=CC=C(Cl)N=N1 YSUHPFLFSFJJCO-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- DVQMPWOLBFKUMM-UHFFFAOYSA-M 2-diethoxyphosphorylacetate Chemical compound CCOP(=O)(CC([O-])=O)OCC DVQMPWOLBFKUMM-UHFFFAOYSA-M 0.000 description 1
- GBHCABUWWQUMAJ-UHFFFAOYSA-N 2-hydrazinoethanol Chemical compound NNCCO GBHCABUWWQUMAJ-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-M 2-methylbenzenesulfonate Chemical compound CC1=CC=CC=C1S([O-])(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-M 0.000 description 1
- BSKHPKMHTQYZBB-UHFFFAOYSA-N 2-methylpyridine Chemical class CC1=CC=CC=N1 BSKHPKMHTQYZBB-UHFFFAOYSA-N 0.000 description 1
- HCDMJFOHIXMBOV-UHFFFAOYSA-N 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-4,7-dihydropyrrolo[4,5]pyrido[1,2-d]pyrimidin-2-one Chemical compound C=1C2=C3N(CC)C(=O)N(C=4C(=C(OC)C=C(OC)C=4F)F)CC3=CN=C2NC=1CN1CCOCC1 HCDMJFOHIXMBOV-UHFFFAOYSA-N 0.000 description 1
- WNEODWDFDXWOLU-QHCPKHFHSA-N 3-[3-(hydroxymethyl)-4-[1-methyl-5-[[5-[(2s)-2-methyl-4-(oxetan-3-yl)piperazin-1-yl]pyridin-2-yl]amino]-6-oxopyridin-3-yl]pyridin-2-yl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one Chemical compound C([C@@H](N(CC1)C=2C=NC(NC=3C(N(C)C=C(C=3)C=3C(=C(N4C(C5=CC=6CC(C)(C)CC=6N5CC4)=O)N=CC=3)CO)=O)=CC=2)C)N1C1COC1 WNEODWDFDXWOLU-QHCPKHFHSA-N 0.000 description 1
- PRORLQAJNJMGAR-UHFFFAOYSA-N 3-chloro-6-methylpyridazine Chemical compound CC1=CC=C(Cl)N=N1 PRORLQAJNJMGAR-UHFFFAOYSA-N 0.000 description 1
- 125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- KVCQTKNUUQOELD-UHFFFAOYSA-N 4-amino-n-[1-(3-chloro-2-fluoroanilino)-6-methylisoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound N=1C=CC2=C(NC(=O)C=3C4=NC=NC(N)=C4SC=3)C(C)=CC=C2C=1NC1=CC=CC(Cl)=C1F KVCQTKNUUQOELD-UHFFFAOYSA-N 0.000 description 1
- KQTGCJMBUBYSLL-UHFFFAOYSA-N 4-piperidin-1-ylmorpholine Chemical compound C1CCCCN1N1CCOCC1 KQTGCJMBUBYSLL-UHFFFAOYSA-N 0.000 description 1
- GEQNDQPPLLXGIJ-QGZVFWFLSA-N 6-[(2R)-6-(4-fluorophenyl)-2-(hydroxymethyl)-2,3-dihydro-1H-imidazo[1,2-b]pyrazol-7-yl]-2-(2-methylphenyl)pyridazin-3-one Chemical compound FC1=CC=C(C=C1)C=1C(=C2N(N1)C[C@@H](N2)CO)C=2C=CC(N(N2)C2=C(C=CC=C2)C)=O GEQNDQPPLLXGIJ-QGZVFWFLSA-N 0.000 description 1
- KLBDYKQTHLWFNO-OAHLLOKOSA-N 6-[(2R)-6-(4-fluorophenyl)-2-methyl-2,3-dihydro-1H-imidazo[1,2-b]pyrazol-7-yl]-2-(2-methylphenyl)pyridazin-3-one Chemical compound C([C@H](NC1=2)C)N1N=C(C=1C=CC(F)=CC=1)C=2C(=N1)C=CC(=O)N1C1=CC=CC=C1C KLBDYKQTHLWFNO-OAHLLOKOSA-N 0.000 description 1
- GEQNDQPPLLXGIJ-KRWDZBQOSA-N 6-[(2S)-6-(4-fluorophenyl)-2-(hydroxymethyl)-2,3-dihydro-1H-imidazo[1,2-b]pyrazol-7-yl]-2-(2-methylphenyl)pyridazin-3-one Chemical compound CC1=CC=CC=C1N1C(=O)C=CC(C=2C(=NN3C[C@@H](CO)NC3=2)C=2C=CC(F)=CC=2)=N1 GEQNDQPPLLXGIJ-KRWDZBQOSA-N 0.000 description 1
- IQDRAWBHXSOJFB-CQSZACIVSA-N 6-[(3R)-6-(2,4-difluorophenyl)-3-methyl-2,3-dihydro-1H-imidazo[1,2-b]pyrazol-7-yl]-2-(2-methylphenyl)pyridazin-3-one Chemical compound C([C@H](N1N=2)C)NC1=C(C1=NN(C(=O)C=C1)C=1C(=CC=CC=1)C)C=2C1=CC=C(F)C=C1F IQDRAWBHXSOJFB-CQSZACIVSA-N 0.000 description 1
- IQDRAWBHXSOJFB-AWEZNQCLSA-N 6-[(3S)-6-(2,4-difluorophenyl)-3-methyl-2,3-dihydro-1H-imidazo[1,2-b]pyrazol-7-yl]-2-(2-methylphenyl)pyridazin-3-one Chemical compound C([C@@H](N1N=2)C)NC1=C(C1=NN(C(=O)C=C1)C=1C(=CC=CC=1)C)C=2C1=CC=C(F)C=C1F IQDRAWBHXSOJFB-AWEZNQCLSA-N 0.000 description 1
- XDHQIVYBPKRWMO-WJOKGBTCSA-N 6-[(5R)-5-[[tert-butyl(diphenyl)silyl]oxymethyl]-2-(4-fluorophenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidin-3-yl]-2-(2-methylphenyl)pyridazin-3-one Chemical compound CC1=CC=CC=C1N1C(=O)C=CC(C=2C(=NN3CC[C@H](CO[Si](C=4C=CC=CC=4)(C=4C=CC=CC=4)C(C)(C)C)NC3=2)C=2C=CC(F)=CC=2)=N1 XDHQIVYBPKRWMO-WJOKGBTCSA-N 0.000 description 1
- YTVBZTSZGHTOSO-OAHLLOKOSA-N 6-[(6R)-2-(2,4-difluorophenyl)-6-hydroxy-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidin-3-yl]-2-(2-methylphenyl)pyridazin-3-one Chemical compound CC1=CC=CC=C1N1C(=O)C=CC(C=2C(=NN3C[C@H](O)CNC3=2)C=2C(=CC(F)=CC=2)F)=N1 YTVBZTSZGHTOSO-OAHLLOKOSA-N 0.000 description 1
- CVSSLCZZPVLZEE-JOCHJYFZSA-N 6-[(6R)-2-(2,4-difluorophenyl)-6-phenylmethoxy-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidin-3-yl]-2-(2-methylphenyl)pyridazin-3-one Chemical compound CC1=CC=CC=C1N1C(=O)C=CC(C=2C(=NN3C[C@@H](CNC3=2)OCC=2C=CC=CC=2)C=2C(=CC(F)=CC=2)F)=N1 CVSSLCZZPVLZEE-JOCHJYFZSA-N 0.000 description 1
- UQGCZJUCUGZCKD-XMMPIXPASA-N 6-[(6R)-2-(4-fluorophenyl)-6-phenylmethoxy-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidin-3-yl]-2-(2-methylphenyl)pyridazin-3-one Chemical compound C(C1=CC=CC=C1)O[C@@H]1CNC=2N(C1)N=C(C2C=2C=CC(N(N2)C2=C(C=CC=C2)C)=O)C2=CC=C(C=C2)F UQGCZJUCUGZCKD-XMMPIXPASA-N 0.000 description 1
- KJJLNRFHQKBHOZ-IBGZPJMESA-N 6-[(6S)-2-(2,4-difluorophenyl)-6-(2,2-dimethylpropoxy)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidin-3-yl]-2-(2-methylphenyl)pyridazin-3-one Chemical compound CC1=CC=CC=C1N1C(=O)C=CC(C=2C(=NN3C[C@H](CNC3=2)OCC(C)(C)C)C=2C(=CC(F)=CC=2)F)=N1 KJJLNRFHQKBHOZ-IBGZPJMESA-N 0.000 description 1
- YTVBZTSZGHTOSO-HNNXBMFYSA-N 6-[(6S)-2-(2,4-difluorophenyl)-6-hydroxy-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidin-3-yl]-2-(2-methylphenyl)pyridazin-3-one Chemical compound CC1=CC=CC=C1N1C(=O)C=CC(C=2C(=NN3C[C@@H](O)CNC3=2)C=2C(=CC(F)=CC=2)F)=N1 YTVBZTSZGHTOSO-HNNXBMFYSA-N 0.000 description 1
- CVSSLCZZPVLZEE-QFIPXVFZSA-N 6-[(6S)-2-(2,4-difluorophenyl)-6-phenylmethoxy-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidin-3-yl]-2-(2-methylphenyl)pyridazin-3-one Chemical compound CC1=CC=CC=C1N1C(=O)C=CC(C=2C(=NN3C[C@H](CNC3=2)OCC=2C=CC=CC=2)C=2C(=CC(F)=CC=2)F)=N1 CVSSLCZZPVLZEE-QFIPXVFZSA-N 0.000 description 1
- WFBOVZJGUWQGMR-YBEGLDIGSA-N 6-[(6Z)-2-(2,4-difluorophenyl)-6-(2-hydroxyethylidene)-5,7-dihydro-4H-pyrazolo[1,5-a]pyrimidin-3-yl]-2-(2-methylphenyl)pyridazin-3-one Chemical compound CC1=CC=CC=C1N1C(=O)C=CC(C=2C(=NN3CC(/CNC3=2)=C\CO)C=2C(=CC(F)=CC=2)F)=N1 WFBOVZJGUWQGMR-YBEGLDIGSA-N 0.000 description 1
- PTJWOGMRIAMKAC-UHFFFAOYSA-N 6-[1-bromo-2-(4-fluorophenyl)-2-oxoethyl]-2-(2-methylphenyl)pyridazin-3-one Chemical compound CC1=CC=CC=C1N1C(=O)C=CC(C(Br)C(=O)C=2C=CC(F)=CC=2)=N1 PTJWOGMRIAMKAC-UHFFFAOYSA-N 0.000 description 1
- LVEPNPSPHAFEJP-UHFFFAOYSA-N 6-[2-(2,4-difluorophenyl)-2-oxoethyl]-2-(2-methylphenyl)pyridazin-3-one Chemical compound CC1=CC=CC=C1N1C(=O)C=CC(CC(=O)C=2C(=CC(F)=CC=2)F)=N1 LVEPNPSPHAFEJP-UHFFFAOYSA-N 0.000 description 1
- SMJHEBYLWSMVQS-UHFFFAOYSA-N 6-[2-(2,4-difluorophenyl)-5-methyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidin-3-yl]-2-(2-methylphenyl)pyridazin-3-one Chemical compound CC1CCn2nc(c(c2N1)-c1ccc(=O)n(n1)-c1ccccc1C)-c1ccc(F)cc1F SMJHEBYLWSMVQS-UHFFFAOYSA-N 0.000 description 1
- QBGSTYHQXNVRQU-UHFFFAOYSA-N 6-[2-(2,4-difluorophenyl)-6,6-bis(hydroxymethyl)-5,7-dihydro-4H-pyrazolo[1,5-a]pyrimidin-3-yl]-2-(2-methylphenyl)pyridazin-3-one Chemical compound CC1=CC=CC=C1N1C(=O)C=CC(C=2C(=NN3CC(CO)(CO)CNC3=2)C=2C(=CC(F)=CC=2)F)=N1 QBGSTYHQXNVRQU-UHFFFAOYSA-N 0.000 description 1
- IYPZYGOMKHRKBC-UHFFFAOYSA-N 6-[2-(2,4-difluorophenyl)-6-[(4-methylpiperazin-1-yl)methyl]-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidin-3-yl]-2-(2-methylphenyl)pyridazin-3-one Chemical compound C1CN(C)CCN1CC1CN2N=C(C=3C(=CC(F)=CC=3)F)C(C3=NN(C(=O)C=C3)C=3C(=CC=CC=3)C)=C2NC1 IYPZYGOMKHRKBC-UHFFFAOYSA-N 0.000 description 1
- COLDRXFPUQNFPN-UHFFFAOYSA-N 6-[2-(2,4-difluorophenyl)spiro[5,7-dihydro-4H-pyrazolo[1,5-a]pyrimidine-6,1'-cyclopropane]-3-yl]-2-(2-methylphenyl)pyridazin-3-one Chemical compound CC1=CC=CC=C1N1C(=O)C=CC(C=2C(=NN3CC4(CC4)CNC3=2)C=2C(=CC(F)=CC=2)F)=N1 COLDRXFPUQNFPN-UHFFFAOYSA-N 0.000 description 1
- UAUMHMOZCGYNCZ-UHFFFAOYSA-N 6-[2-(4-fluorophenyl)-4-(3-hydroxypropyl)-6,7-dihydro-5h-pyrazolo[1,5-a]pyrimidin-3-yl]-2-(2-methylphenyl)pyridazin-3-one Chemical compound CC1=CC=CC=C1N1C(=O)C=CC(C2=C3N(CCCO)CCCN3N=C2C=2C=CC(F)=CC=2)=N1 UAUMHMOZCGYNCZ-UHFFFAOYSA-N 0.000 description 1
- YJTHZVZNHQPGFS-UHFFFAOYSA-N 6-[2-(4-fluorophenyl)-6,6-bis(hydroxymethyl)-5,7-dihydro-4H-pyrazolo[1,5-a]pyrimidin-3-yl]-2-(2-methylphenyl)pyridazin-3-one Chemical compound CC1=CC=CC=C1N1C(=O)C=CC(C=2C(=NN3CC(CO)(CO)CNC3=2)C=2C=CC(F)=CC=2)=N1 YJTHZVZNHQPGFS-UHFFFAOYSA-N 0.000 description 1
- WKXKZDMPLVIEEF-UHFFFAOYSA-N 6-[2-(4-fluorophenyl)-6-(propan-2-ylamino)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidin-3-yl]-2-(2-methylphenyl)pyridazin-3-one Chemical compound N=1N2CC(NC(C)C)CNC2=C(C2=NN(C(=O)C=C2)C=2C(=CC=CC=2)C)C=1C1=CC=C(F)C=C1 WKXKZDMPLVIEEF-UHFFFAOYSA-N 0.000 description 1
- IRYCISXFCUVJBC-UHFFFAOYSA-N 6-[2-(4-fluorophenyl)-6-[(2-methoxyethylamino)methyl]-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidin-3-yl]-2-(2-methylphenyl)pyridazin-3-one Chemical compound N=1N2CC(CNCCOC)CNC2=C(C2=NN(C(=O)C=C2)C=2C(=CC=CC=2)C)C=1C1=CC=C(F)C=C1 IRYCISXFCUVJBC-UHFFFAOYSA-N 0.000 description 1
- SXKMPLDBLZUHKW-UHFFFAOYSA-N 6-[2-(4-fluorophenyl)spiro[5,7-dihydro-4H-pyrazolo[1,5-a]pyrimidine-6,4'-oxane]-3-yl]-2-(2-methylphenyl)pyridazin-3-one Chemical compound CC1=CC=CC=C1N1C(=O)C=CC(C=2C(=NN3CC4(CCOCC4)CNC3=2)C=2C=CC(F)=CC=2)=N1 SXKMPLDBLZUHKW-UHFFFAOYSA-N 0.000 description 1
- OFOZYHWCAIWHTG-UHFFFAOYSA-N 6-[3-[(3-bromo-2,2-difluoropropyl)amino]-5-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-(2-methylphenyl)pyridazin-3-one Chemical compound CC1=CC=CC=C1N1C(=O)C=CC(C=2C(=NNC=2NCC(F)(F)CBr)C=2C=CC(F)=CC=2)=N1 OFOZYHWCAIWHTG-UHFFFAOYSA-N 0.000 description 1
- RZJYGPBMFYKGMH-WJOKGBTCSA-N 6-[3-[[(2R)-1-[tert-butyl(diphenyl)silyl]oxy-4-hydroxybutan-2-yl]amino]-5-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-(2-methylphenyl)pyridazin-3-one Chemical compound CC1=CC=CC=C1N1C(=O)C=CC(C=2C(=NNC=2N[C@H](CCO)CO[Si](C=2C=CC=CC=2)(C=2C=CC=CC=2)C(C)(C)C)C=2C=CC(F)=CC=2)=N1 RZJYGPBMFYKGMH-WJOKGBTCSA-N 0.000 description 1
- IJFPZSANCZDKFH-UHFFFAOYSA-N 6-[3-[[1-(bromomethyl)cyclohexyl]methylamino]-5-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-(2-methylphenyl)pyridazin-3-one Chemical compound CC1=CC=CC=C1N1C(=O)C=CC(C=2C(=NNC=2NCC2(CBr)CCCCC2)C=2C=CC(F)=CC=2)=N1 IJFPZSANCZDKFH-UHFFFAOYSA-N 0.000 description 1
- QZKLUZBNDKRRSA-UHFFFAOYSA-N 6-[4-ethyl-2-(4-fluorophenyl)-6,7-dihydro-5h-pyrazolo[1,5-a]pyrimidin-3-yl]-2-(2-methylphenyl)pyridazin-3-one Chemical compound C=12N(CC)CCCN2N=C(C=2C=CC(F)=CC=2)C=1C(=N1)C=CC(=O)N1C1=CC=CC=C1C QZKLUZBNDKRRSA-UHFFFAOYSA-N 0.000 description 1
- YGNBPSOVRGCFIR-CQSZACIVSA-N 6-[5-(2,4-difluorophenyl)-3-[[(2R)-2-hydroxypropyl]amino]-1H-pyrazol-4-yl]-2-(2-methylphenyl)pyridazin-3-one Chemical compound C[C@@H](O)CNC=1NN=C(C=2C(=CC(F)=CC=2)F)C=1C(=N1)C=CC(=O)N1C1=CC=CC=C1C YGNBPSOVRGCFIR-CQSZACIVSA-N 0.000 description 1
- XSVSPTUJFMTGMK-JOCHJYFZSA-N 6-[5-(2,4-difluorophenyl)-3-[[(2R)-3-hydroxy-2-phenylmethoxypropyl]amino]-1H-pyrazol-4-yl]-2-(2-methylphenyl)pyridazin-3-one Chemical compound CC1=CC=CC=C1N1C(=O)C=CC(C=2C(=NNC=2NC[C@H](CO)OCC=2C=CC=CC=2)C=2C(=CC(F)=CC=2)F)=N1 XSVSPTUJFMTGMK-JOCHJYFZSA-N 0.000 description 1
- YGNBPSOVRGCFIR-AWEZNQCLSA-N 6-[5-(2,4-difluorophenyl)-3-[[(2S)-2-hydroxypropyl]amino]-1H-pyrazol-4-yl]-2-(2-methylphenyl)pyridazin-3-one Chemical compound C[C@H](O)CNC=1NN=C(C=2C(=CC(F)=CC=2)F)C=1C(=N1)C=CC(=O)N1C1=CC=CC=C1C YGNBPSOVRGCFIR-AWEZNQCLSA-N 0.000 description 1
- XSVSPTUJFMTGMK-QFIPXVFZSA-N 6-[5-(2,4-difluorophenyl)-3-[[(2S)-3-hydroxy-2-phenylmethoxypropyl]amino]-1H-pyrazol-4-yl]-2-(2-methylphenyl)pyridazin-3-one Chemical compound CC1=CC=CC=C1N1C(=O)C=CC(C=2C(=NNC=2NC[C@@H](CO)OCC=2C=CC=CC=2)C=2C(=CC(F)=CC=2)F)=N1 XSVSPTUJFMTGMK-QFIPXVFZSA-N 0.000 description 1
- XQEMUHJMVBQFMZ-UHFFFAOYSA-N 6-[5-(2,4-difluorophenyl)-3-[[3-(hydroxymethyl)azetidin-3-yl]methylamino]-1H-pyrazol-4-yl]-2-(2-methylphenyl)pyridazin-3-one Chemical compound CC1=CC=CC=C1N1C(=O)C=CC(C=2C(=NNC=2NCC2(CO)CNC2)C=2C(=CC(F)=CC=2)F)=N1 XQEMUHJMVBQFMZ-UHFFFAOYSA-N 0.000 description 1
- RFDUKUVNOMTUML-UHFFFAOYSA-N 6-[5-(4-fluorophenyl)-3-(2-hydroxyethylamino)-1H-pyrazol-4-yl]-2-(2-methylphenyl)pyridazin-3-one Chemical compound CC1=CC=CC=C1N1C(=O)C=CC(C=2C(=NNC=2NCCO)C=2C=CC(F)=CC=2)=N1 RFDUKUVNOMTUML-UHFFFAOYSA-N 0.000 description 1
- DUUMSTRXDRZHMO-XMMPIXPASA-N 6-[5-(4-fluorophenyl)-3-[[(2R)-1-hydroxy-3-phenylmethoxypropan-2-yl]amino]-1H-pyrazol-4-yl]-2-(2-methylphenyl)pyridazin-3-one Chemical compound CC1=CC=CC=C1N1C(=O)C=CC(C=2C(=NNC=2N[C@H](CO)COCC=2C=CC=CC=2)C=2C=CC(F)=CC=2)=N1 DUUMSTRXDRZHMO-XMMPIXPASA-N 0.000 description 1
- BGAWFBPWJBJWQQ-XMMPIXPASA-N 6-[5-(4-fluorophenyl)-3-[[(2R)-3-hydroxy-2-phenylmethoxypropyl]amino]-1H-pyrazol-4-yl]-2-(2-methylphenyl)pyridazin-3-one Chemical compound C(C1=CC=CC=C1)O[C@H](CNC1=C(C(=NN1)C1=CC=C(C=C1)F)C=1C=CC(N(N1)C1=C(C=CC=C1)C)=O)CO BGAWFBPWJBJWQQ-XMMPIXPASA-N 0.000 description 1
- DUUMSTRXDRZHMO-DEOSSOPVSA-N 6-[5-(4-fluorophenyl)-3-[[(2S)-1-hydroxy-3-phenylmethoxypropan-2-yl]amino]-1H-pyrazol-4-yl]-2-(2-methylphenyl)pyridazin-3-one Chemical compound C(C1=CC=CC=C1)OC[C@H](CO)NC1=C(C(=NN1)C1=CC=C(C=C1)F)C=1C=CC(N(N1)C1=C(C=CC=C1)C)=O DUUMSTRXDRZHMO-DEOSSOPVSA-N 0.000 description 1
- MQJDMIHVURRJJI-UHFFFAOYSA-N 6-[5-(4-fluorophenyl)-3-[[1-(hydroxymethyl)cyclobutyl]methylamino]-1H-pyrazol-4-yl]-2-(2-methylphenyl)pyridazin-3-one Chemical compound FC1=CC=C(C=C1)C1=NNC(=C1C=1C=CC(N(N1)C1=C(C=CC=C1)C)=O)NCC1(CCC1)CO MQJDMIHVURRJJI-UHFFFAOYSA-N 0.000 description 1
- FZJMYEUCDVULBZ-UHFFFAOYSA-N 6-[5-(4-fluorophenyl)-3-[[1-(hydroxymethyl)cyclopropyl]methylamino]-1H-pyrazol-4-yl]-2-(2-methylphenyl)pyridazin-3-one Chemical compound CC1=CC=CC=C1N1C(=O)C=CC(C=2C(=NNC=2NCC2(CO)CC2)C=2C=CC(F)=CC=2)=N1 FZJMYEUCDVULBZ-UHFFFAOYSA-N 0.000 description 1
- JJVHPWQXIAMHGP-UHFFFAOYSA-N 6-[5-(4-fluorophenyl)-3-[[2-(hydroxymethyl)-3-[(2-methylpropan-2-yl)oxy]propyl]amino]-1H-pyrazol-4-yl]-2-(2-methylphenyl)pyridazin-3-one Chemical compound CC1=CC=CC=C1N1C(=O)C=CC(C=2C(=NNC=2NCC(CO)COC(C)(C)C)C=2C=CC(F)=CC=2)=N1 JJVHPWQXIAMHGP-UHFFFAOYSA-N 0.000 description 1
- ULNZFSAEAINDOS-UHFFFAOYSA-N 6-[5-(4-fluorophenyl)-3-[[4-(2-hydroxyethyl)oxan-4-yl]amino]-1H-pyrazol-4-yl]-2-(2-methylphenyl)pyridazin-3-one Chemical compound FC1=CC=C(C=C1)C1=NNC(=C1C=1C=CC(N(N1)C1=C(C=CC=C1)C)=O)NC1(CCOCC1)CCO ULNZFSAEAINDOS-UHFFFAOYSA-N 0.000 description 1
- CPBZHGVVVSXEQL-UHFFFAOYSA-N 6-[5-(4-fluorophenyl)-3-[[4-(hydroxymethyl)oxan-4-yl]methylamino]-1H-pyrazol-4-yl]-2-(2-methylphenyl)pyridazin-3-one Chemical compound CC1=CC=CC=C1N1C(=O)C=CC(C=2C(=NNC=2NCC2(CO)CCOCC2)C=2C=CC(F)=CC=2)=N1 CPBZHGVVVSXEQL-UHFFFAOYSA-N 0.000 description 1
- NAOPPTFNXNWXKU-UHFFFAOYSA-N 6-[5-(ethylamino)-3-(4-fluorophenyl)-1-(3-hydroxypropyl)pyrazol-4-yl]-2-(2-methylphenyl)pyridazin-3-one Chemical compound N=1N(CCCO)C(NCC)=C(C2=NN(C(=O)C=C2)C=2C(=CC=CC=2)C)C=1C1=CC=C(F)C=C1 NAOPPTFNXNWXKU-UHFFFAOYSA-N 0.000 description 1
- VLISFZVUIJLKDN-UHFFFAOYSA-N 6-[6,6-difluoro-2-(4-fluorophenyl)-5,7-dihydro-4H-pyrazolo[1,5-a]pyrimidin-3-yl]-2-(2-methylphenyl)pyridazin-3-one Chemical compound CC1=CC=CC=C1N1C(=O)C=CC(C=2C(=NN3CC(F)(F)CNC3=2)C=2C=CC(F)=CC=2)=N1 VLISFZVUIJLKDN-UHFFFAOYSA-N 0.000 description 1
- HRNZQXPXFJIIQV-UHFFFAOYSA-N 6-[6-(4-fluorophenyl)-1-(3-hydroxypropyl)-2,3-dihydroimidazo[1,2-b]pyrazol-7-yl]-2-(2-methylphenyl)pyridazin-3-one Chemical compound CC1=CC=CC=C1N1C(=O)C=CC(C2=C3N(CCCO)CCN3N=C2C=2C=CC(F)=CC=2)=N1 HRNZQXPXFJIIQV-UHFFFAOYSA-N 0.000 description 1
- VIFHJSXUQNFBQF-UHFFFAOYSA-N 6-[6-(aminomethyl)-2-(2,4-difluorophenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidin-3-yl]-2-(2-methylphenyl)pyridazin-3-one Chemical compound CC1=CC=CC=C1N1C(=O)C=CC(C=2C(=NN3CC(CN)CNC3=2)C=2C(=CC(F)=CC=2)F)=N1 VIFHJSXUQNFBQF-UHFFFAOYSA-N 0.000 description 1
- NJFCZMQCMAUAOR-UHFFFAOYSA-N 6-[6-(dimethylamino)-2-(4-fluorophenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidin-3-yl]-2-(2-methylphenyl)pyridazin-3-one Chemical compound N=1N2CC(N(C)C)CNC2=C(C2=NN(C(=O)C=C2)C=2C(=CC=CC=2)C)C=1C1=CC=C(F)C=C1 NJFCZMQCMAUAOR-UHFFFAOYSA-N 0.000 description 1
- OHOFNHDOSHDLTO-UHFFFAOYSA-N 6-[6-(hydroxymethyl)-2-(3-methylphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidin-3-yl]-2-(2-methylphenyl)pyridazin-3-one Chemical compound CC1=CC=CC(C=2C(=C3NCC(CO)CN3N=2)C2=NN(C(=O)C=C2)C=2C(=CC=CC=2)C)=C1 OHOFNHDOSHDLTO-UHFFFAOYSA-N 0.000 description 1
- CBHCUXNXILTYGU-UHFFFAOYSA-N 6-[6-(methylaminomethyl)-2-(3-methylphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidin-3-yl]-2-(2-methylphenyl)pyridazin-3-one Chemical compound N=1N2CC(CNC)CNC2=C(C2=NN(C(=O)C=C2)C=2C(=CC=CC=2)C)C=1C1=CC=CC(C)=C1 CBHCUXNXILTYGU-UHFFFAOYSA-N 0.000 description 1
- ZUOOJMPPCLOLON-UHFFFAOYSA-N 6-[6-[(dibenzylamino)methyl]-2-(2,4-difluorophenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidin-3-yl]-2-(2-methylphenyl)pyridazin-3-one Chemical compound CC1=CC=CC=C1N1C(=O)C=CC(C=2C(=NN3CC(CN(CC=4C=CC=CC=4)CC=4C=CC=CC=4)CNC3=2)C=2C(=CC(F)=CC=2)F)=N1 ZUOOJMPPCLOLON-UHFFFAOYSA-N 0.000 description 1
- AVVPXHHWRGMYIR-UHFFFAOYSA-N 6-[6-[(dimethylamino)methyl]-2-(3,5-dimethylphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidin-3-yl]-2-(2-methylphenyl)pyridazin-3-one Chemical compound N=1N2CC(CN(C)C)CNC2=C(C2=NN(C(=O)C=C2)C=2C(=CC=CC=2)C)C=1C1=CC(C)=CC(C)=C1 AVVPXHHWRGMYIR-UHFFFAOYSA-N 0.000 description 1
- FPJXLYQKGIRHQZ-UHFFFAOYSA-N 6-[6-[(dimethylamino)methyl]-2-(4-fluorophenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidin-3-yl]-2-(2-methylphenyl)pyridazin-3-one Chemical compound N=1N2CC(CN(C)C)CNC2=C(C2=NN(C(=O)C=C2)C=2C(=CC=CC=2)C)C=1C1=CC=C(F)C=C1 FPJXLYQKGIRHQZ-UHFFFAOYSA-N 0.000 description 1
- ICLKJDINTLONMD-UHFFFAOYSA-N 6-[6-[(tert-butylamino)methyl]-2-(2,4-difluorophenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidin-3-yl]-2-(2-methylphenyl)pyridazin-3-one Chemical compound CC1=CC=CC=C1N1C(=O)C=CC(C=2C(=NN3CC(CNC(C)(C)C)CNC3=2)C=2C(=CC(F)=CC=2)F)=N1 ICLKJDINTLONMD-UHFFFAOYSA-N 0.000 description 1
- KLSHSMNMJDGFSW-UHFFFAOYSA-N 6-[6-[(tert-butylamino)methyl]-2-(4-fluorophenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidin-3-yl]-2-(2-methylphenyl)pyridazin-3-one Chemical compound CC1=CC=CC=C1N1C(=O)C=CC(C=2C(=NN3CC(CNC(C)(C)C)CNC3=2)C=2C=CC(F)=CC=2)=N1 KLSHSMNMJDGFSW-UHFFFAOYSA-N 0.000 description 1
- JMAJKSHPRHKRQM-UHFFFAOYSA-N 6-[[2-(4-fluorophenyl)-1,3-dioxolan-2-yl]methyl]-2-(2-methylphenyl)pyridazin-3-one Chemical compound CC1=CC=CC=C1N1C(=O)C=CC(CC2(OCCO2)C=2C=CC(F)=CC=2)=N1 JMAJKSHPRHKRQM-UHFFFAOYSA-N 0.000 description 1
- CYJRNFFLTBEQSQ-UHFFFAOYSA-N 8-(3-methyl-1-benzothiophen-5-yl)-N-(4-methylsulfonylpyridin-3-yl)quinoxalin-6-amine Chemical compound CS(=O)(=O)C1=C(C=NC=C1)NC=1C=C2N=CC=NC2=C(C=1)C=1C=CC2=C(C(=CS2)C)C=1 CYJRNFFLTBEQSQ-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 229910021590 Copper(II) bromide Inorganic materials 0.000 description 1
- HTJDQJBWANPRPF-UHFFFAOYSA-N Cyclopropylamine Chemical compound NC1CC1 HTJDQJBWANPRPF-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 108010008165 Etanercept Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 229910010084 LiAlH4 Inorganic materials 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 1
- AYCPARAPKDAOEN-LJQANCHMSA-N N-[(1S)-2-(dimethylamino)-1-phenylethyl]-6,6-dimethyl-3-[(2-methyl-4-thieno[3,2-d]pyrimidinyl)amino]-1,4-dihydropyrrolo[3,4-c]pyrazole-5-carboxamide Chemical compound C1([C@H](NC(=O)N2C(C=3NN=C(NC=4C=5SC=CC=5N=C(C)N=4)C=3C2)(C)C)CN(C)C)=CC=CC=C1 AYCPARAPKDAOEN-LJQANCHMSA-N 0.000 description 1
- QVUXQVOMHMBEEZ-UHFFFAOYSA-N N-cyclopropyl-2-(4-fluorophenyl)-3-[1-(2-methylphenyl)-6-oxopyridazin-3-yl]-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-6-carboxamide Chemical compound CC1=CC=CC=C1N1C(=O)C=CC(C=2C(=NN3CC(CNC3=2)C(=O)NC2CC2)C=2C=CC(F)=CC=2)=N1 QVUXQVOMHMBEEZ-UHFFFAOYSA-N 0.000 description 1
- LFTLOKWAGJYHHR-UHFFFAOYSA-N N-methylmorpholine N-oxide Chemical compound CN1(=O)CCOCC1 LFTLOKWAGJYHHR-UHFFFAOYSA-N 0.000 description 1
- AYDIZIVBZWNEGJ-UHFFFAOYSA-N OBO.CC1=CC=CC=C1 Chemical compound OBO.CC1=CC=CC=C1 AYDIZIVBZWNEGJ-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- TUEIURIZJQRMQE-UHFFFAOYSA-N [2-(tert-butylsulfamoyl)phenyl]boronic acid Chemical compound CC(C)(C)NS(=O)(=O)C1=CC=CC=C1B(O)O TUEIURIZJQRMQE-UHFFFAOYSA-N 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 125000005194 alkoxycarbonyloxy group Chemical group 0.000 description 1
- 125000005281 alkyl ureido group Chemical group 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- BIVUUOPIAYRCAP-UHFFFAOYSA-N aminoazanium;chloride Chemical compound Cl.NN BIVUUOPIAYRCAP-UHFFFAOYSA-N 0.000 description 1
- 125000005124 aminocycloalkyl group Chemical group 0.000 description 1
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 description 1
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- JDXKTOBMLZLCSB-UHFFFAOYSA-N anilinothiourea Chemical compound NC(=S)NNC1=CC=CC=C1 JDXKTOBMLZLCSB-UHFFFAOYSA-N 0.000 description 1
- 125000005428 anthryl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C3C(*)=C([H])C([H])=C([H])C3=C([H])C2=C1[H] 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000003435 antirheumatic agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000009697 arginine Nutrition 0.000 description 1
- 125000005098 aryl alkoxy carbonyl group Chemical group 0.000 description 1
- 125000002102 aryl alkyloxo group Chemical group 0.000 description 1
- 125000004658 aryl carbonyl amino group Chemical group 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 238000010533 azeotropic distillation Methods 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- SYXSMTCXQUGEIJ-UHFFFAOYSA-N benzyl 4-(2-hydroxyethyl)piperidine-1-carboxylate Chemical compound C1CC(CCO)CCN1C(=O)OCC1=CC=CC=C1 SYXSMTCXQUGEIJ-UHFFFAOYSA-N 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000002051 biphasic effect Effects 0.000 description 1
- 125000006267 biphenyl group Chemical group 0.000 description 1
- XGIUDIMNNMKGDE-UHFFFAOYSA-N bis(trimethylsilyl)azanide Chemical compound C[Si](C)(C)[N-][Si](C)(C)C XGIUDIMNNMKGDE-UHFFFAOYSA-N 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 125000005997 bromomethyl group Chemical group 0.000 description 1
- 125000006251 butylcarbonyl group Chemical group 0.000 description 1
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- KVJGAHKNJAOOOG-UHFFFAOYSA-N chembl2170289 Chemical compound CC1=CC=CC=C1N1C(=O)C=CC(C=2C(=NN3CCNC3=2)C=2C=CC(F)=CC=2)=N1 KVJGAHKNJAOOOG-UHFFFAOYSA-N 0.000 description 1
- QXYRMVUWXFWUKP-QGZVFWFLSA-N chembl2170292 Chemical compound CC1=CC=CC=C1N1C(=O)C=CC(C=2C(=NN3C[C@H](O)CNC3=2)C=2C=CC(F)=CC=2)=N1 QXYRMVUWXFWUKP-QGZVFWFLSA-N 0.000 description 1
- QXYRMVUWXFWUKP-KRWDZBQOSA-N chembl2170293 Chemical compound CC1=CC=CC=C1N1C(=O)C=CC(C=2C(=NN3C[C@@H](O)CNC3=2)C=2C=CC(F)=CC=2)=N1 QXYRMVUWXFWUKP-KRWDZBQOSA-N 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004296 chiral HPLC Methods 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- NWFNSTOSIVLCJA-UHFFFAOYSA-L copper;diacetate;hydrate Chemical compound O.[Cu+2].CC([O-])=O.CC([O-])=O NWFNSTOSIVLCJA-UHFFFAOYSA-L 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 150000003946 cyclohexylamines Chemical class 0.000 description 1
- AIMMVWOEOZMVMS-UHFFFAOYSA-N cyclopropanecarboxamide Chemical compound NC(=O)C1CC1 AIMMVWOEOZMVMS-UHFFFAOYSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 125000006264 diethylaminomethyl group Chemical group [H]C([H])([H])C([H])([H])N(C([H])([H])*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004212 difluorophenyl group Chemical group 0.000 description 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
- 238000011549 displacement method Methods 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- FCZCIXQGZOUIDN-UHFFFAOYSA-N ethyl 2-diethoxyphosphinothioyloxyacetate Chemical compound CCOC(=O)COP(=S)(OCC)OCC FCZCIXQGZOUIDN-UHFFFAOYSA-N 0.000 description 1
- UMPRJGKLMUDRHL-UHFFFAOYSA-N ethyl 4-fluorobenzoate Chemical compound CCOC(=O)C1=CC=C(F)C=C1 UMPRJGKLMUDRHL-UHFFFAOYSA-N 0.000 description 1
- MSMGXWFHBSCQFB-UHFFFAOYSA-N ethyl cyanoformate Chemical compound CCOC(=O)C#N MSMGXWFHBSCQFB-UHFFFAOYSA-N 0.000 description 1
- 125000004672 ethylcarbonyl group Chemical group [H]C([H])([H])C([H])([H])C(*)=O 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 125000001207 fluorophenyl group Chemical group 0.000 description 1
- 210000002683 foot Anatomy 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 125000004871 hexylcarbonyl group Chemical group C(CCCCC)C(=O)* 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine hydrate Chemical compound O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 1
- 125000000717 hydrazino group Chemical group [H]N([*])N([H])[H] 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- AQYSYJUIMQTRMV-UHFFFAOYSA-N hypofluorous acid Chemical group FO AQYSYJUIMQTRMV-UHFFFAOYSA-N 0.000 description 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 125000006261 methyl amino sulfonyl group Chemical group [H]N(C([H])([H])[H])S(*)(=O)=O 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- DUWWHGPELOTTOE-UHFFFAOYSA-N n-(5-chloro-2,4-dimethoxyphenyl)-3-oxobutanamide Chemical compound COC1=CC(OC)=C(NC(=O)CC(C)=O)C=C1Cl DUWWHGPELOTTOE-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- BLMBXPYWNVGCMB-UHFFFAOYSA-N o-phenyl n-[[4-(hydroxymethyl)thian-4-yl]methyl]carbamothioate Chemical compound C=1C=CC=CC=1OC(=S)NCC1(CO)CCSCC1 BLMBXPYWNVGCMB-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 1
- 229910000489 osmium tetroxide Inorganic materials 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 125000004675 pentylcarbonyl group Chemical group C(CCCC)C(=O)* 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 230000004526 pharmaceutical effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 208000030428 polyarticular arthritis Diseases 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004673 propylcarbonyl group Chemical group 0.000 description 1
- 125000004289 pyrazol-3-yl group Chemical group [H]N1N=C(*)C([H])=C1[H] 0.000 description 1
- USPWKWBDZOARPV-UHFFFAOYSA-N pyrazolidine Chemical compound C1CNNC1 USPWKWBDZOARPV-UHFFFAOYSA-N 0.000 description 1
- LDIJKUBTLZTFRG-UHFFFAOYSA-N pyrazolo[1,5-a]pyrimidine Chemical compound N1=CC=CN2N=CC=C21 LDIJKUBTLZTFRG-UHFFFAOYSA-N 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- JQRYUMGHOUYJFW-UHFFFAOYSA-N pyridine;trihydrobromide Chemical compound [Br-].[Br-].[Br-].C1=CC=[NH+]C=C1.C1=CC=[NH+]C=C1.C1=CC=[NH+]C=C1 JQRYUMGHOUYJFW-UHFFFAOYSA-N 0.000 description 1
- 150000003222 pyridines Chemical class 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 229940116176 remicade Drugs 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- XGVXKJKTISMIOW-ZDUSSCGKSA-N simurosertib Chemical compound N1N=CC(C=2SC=3C(=O)NC(=NC=3C=2)[C@H]2N3CCC(CC3)C2)=C1C XGVXKJKTISMIOW-ZDUSSCGKSA-N 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 125000006318 tert-butyl amino group Chemical group [H]N(*)C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical class CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 1
- JABYJIQOLGWMQW-UHFFFAOYSA-N undec-4-ene Chemical compound CCCCCCC=CCCC JABYJIQOLGWMQW-UHFFFAOYSA-N 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/20—Spiro-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US71282505P | 2005-09-01 | 2005-09-01 | |
| US60/712,825 | 2005-09-01 | ||
| PCT/JP2006/317691 WO2007026950A1 (en) | 2005-09-01 | 2006-08-31 | Pyridazinone derivatives used for the treatment of pain |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0617100A2 true BRPI0617100A2 (pt) | 2011-07-12 |
Family
ID=37607561
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0617100-1A BRPI0617100A2 (pt) | 2005-09-01 | 2006-08-31 | composto derivado de piridazinona, composição farmacêutica, método para previnir ou tratar uma doença e uso de um composto derivado de piridazinona |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20090042856A1 (enExample) |
| EP (1) | EP1919919A1 (enExample) |
| JP (1) | JP5066516B2 (enExample) |
| KR (1) | KR20080049758A (enExample) |
| CN (1) | CN101268079B (enExample) |
| AU (1) | AU2006285599A1 (enExample) |
| BR (1) | BRPI0617100A2 (enExample) |
| CA (1) | CA2620740A1 (enExample) |
| IL (1) | IL189697A0 (enExample) |
| NO (1) | NO20081572L (enExample) |
| RU (1) | RU2008112290A (enExample) |
| TW (1) | TW200745034A (enExample) |
| WO (1) | WO2007026950A1 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200904421A (en) * | 2007-05-03 | 2009-02-01 | Astellas Pharma Inc | New compounds |
| WO2009005675A1 (en) | 2007-06-28 | 2009-01-08 | Abbott Laboratories | Novel triazolopyridazines |
| EP2296653B1 (en) | 2008-06-03 | 2016-01-27 | Intermune, Inc. | Compounds and methods for treating inflammatory and fibrotic disorders |
| CN103180300B (zh) * | 2010-09-08 | 2015-10-07 | 住友化学株式会社 | 制备哒嗪酮化合物的方法和其中间体 |
| UA114490C2 (uk) | 2011-10-06 | 2017-06-26 | Байєр Інтеллектуал Проперті Гмбх | Гетероциклілпіри(mі)динілпіразоли як фунгіциди |
| JO3407B1 (ar) | 2012-05-31 | 2019-10-20 | Eisai R&D Man Co Ltd | مركبات رباعي هيدرو بيرازولو بيريميدين |
| AR092742A1 (es) | 2012-10-02 | 2015-04-29 | Intermune Inc | Piridinonas antifibroticas |
| PL2989106T3 (pl) | 2013-04-25 | 2017-08-31 | Beigene, Ltd. | Połączone związki heterocykliczne jako inhibitory kinazy białkowej |
| SMT202300039T1 (it) | 2013-09-13 | 2023-03-17 | Beigene Switzerland Gmbh | Anticorpi anti-pd1 e loro uso come terapia e per diagnostica |
| RU2692485C2 (ru) | 2014-04-02 | 2019-06-25 | Интермьюн, Инк. | Противофиброзные пиридиноны |
| TWI726608B (zh) | 2014-07-03 | 2021-05-01 | 英屬開曼群島商百濟神州有限公司 | 抗pd-l1抗體及其作為治療及診斷之用途 |
| CN106146404B (zh) * | 2015-04-15 | 2020-03-20 | 江苏恩华药业股份有限公司 | 哒嗪酮类衍生物及其应用 |
| WO2018007885A1 (en) | 2016-07-05 | 2018-01-11 | Beigene, Ltd. | COMBINATION OF A PD-l ANTAGONIST AND A RAF INHIBITOR FOR TREATING CANCER |
| IL293319B1 (en) | 2016-08-16 | 2026-01-01 | Beone Medicines Ltd | Crystal structure of s)–7–(1–acryloylpiperidin–4–yl)–2–(4–)phenoxyphenyl)–4,5,6,7–tetra–hydropyrazolo(1,5–a)pyrimidine–3–carboxamide, methods of preparation and uses thereof |
| CN110087680B (zh) | 2016-08-19 | 2024-03-19 | 百济神州有限公司 | 使用包含btk抑制剂的组合产品治疗癌症 |
| UA125852C2 (uk) | 2016-08-31 | 2022-06-22 | Ле Лаборатуар Сервьє | Інгібітори клітинних метаболічних процесів |
| EP3824906A1 (en) | 2016-12-21 | 2021-05-26 | Amgen Inc. | Anti-tnf alpha antibody formulations |
| EP3573989A4 (en) | 2017-01-25 | 2020-11-18 | Beigene, Ltd. | CRYSTALLINE FORMS OF (S) -7- (1- (BUT-2-YNOYL) PIPERIDIN-4-YL) -2- (4-PHENOXYPHENYL) -4, 5, 6, 7-TETRAHY DROPYRAZOLO [1, 5-A ] PYRIMIDINE-3-CARBOXAMIDE, PREPARATION AND ASSOCIATED USES |
| US10617680B2 (en) * | 2017-04-18 | 2020-04-14 | Celgene Quanticel Research, Inc. | Therapeutic compounds |
| EP3645569A4 (en) | 2017-06-26 | 2021-03-24 | BeiGene, Ltd. | IMMUNOTHERAPY FOR LIVER CELL CARCINOMA |
| WO2019034009A1 (en) | 2017-08-12 | 2019-02-21 | Beigene, Ltd. | BTK INHIBITOR WITH ENHANCED DOUBLE SELECTIVITY |
| ES2927715T3 (es) | 2017-10-05 | 2022-11-10 | Fulcrum Therapeutics Inc | Inhibidores de la quinasa p38 reducen la expresión de dux4 y de los genes que le siguen para el tratamiento de la FSHD |
| US11786529B2 (en) | 2017-11-29 | 2023-10-17 | Beigene Switzerland Gmbh | Treatment of indolent or aggressive B-cell lymphomas using a combination comprising BTK inhibitors |
| EP3981399A4 (en) | 2019-06-10 | 2023-05-31 | BeiGene Switzerland GmbH | ORAL SOLID TABLET WITH A TYROSINE KINAS INHIBITOR AND METHOD OF MANUFACTURE THEREOF |
| TW202112368A (zh) | 2019-06-13 | 2021-04-01 | 荷蘭商法西歐知識產權股份有限公司 | 用於治療有關dux4表現之疾病的抑制劑組合 |
| US11786531B1 (en) | 2022-06-08 | 2023-10-17 | Beigene Switzerland Gmbh | Methods of treating B-cell proliferative disorder |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5356897A (en) * | 1991-09-09 | 1994-10-18 | Fujisawa Pharmaceutical Co., Ltd. | 3-(heteroaryl)-pyrazololi[1,5-a]pyrimidines |
| US20040152659A1 (en) * | 1999-05-12 | 2004-08-05 | Fujisawa Pharmaceutical Co. Ltd. | Method for the treatment of parkinson's disease comprising administering an A1A2a receptor dual antagonist |
| AR023966A1 (es) * | 1999-05-12 | 2002-09-04 | Fujisawa Pharmaceutical Co | Una composicion farmaceutica para la prevencion y/o el tratamiento de la enfermedad de parkinson y los sintomas concomitantes de la misma, y el uso de unantagonista dual receptor de adenosina a1 a2a para preparar dicha composicion |
| AUPQ441499A0 (en) * | 1999-12-02 | 2000-01-06 | Fujisawa Pharmaceutical Co., Ltd. | Novel compound |
| WO2006038734A1 (en) * | 2004-10-08 | 2006-04-13 | Astellas Pharma Inc. | Pyridazinone derivatives cytokines inhibitors |
-
2006
- 2006-08-31 TW TW095132103A patent/TW200745034A/zh unknown
- 2006-08-31 AU AU2006285599A patent/AU2006285599A1/en not_active Abandoned
- 2006-08-31 CN CN2006800322174A patent/CN101268079B/zh not_active Expired - Fee Related
- 2006-08-31 RU RU2008112290/04A patent/RU2008112290A/ru not_active Application Discontinuation
- 2006-08-31 EP EP06797567A patent/EP1919919A1/en not_active Withdrawn
- 2006-08-31 KR KR1020087007056A patent/KR20080049758A/ko not_active Ceased
- 2006-08-31 CA CA002620740A patent/CA2620740A1/en not_active Abandoned
- 2006-08-31 US US12/063,766 patent/US20090042856A1/en not_active Abandoned
- 2006-08-31 JP JP2008511498A patent/JP5066516B2/ja not_active Expired - Fee Related
- 2006-08-31 BR BRPI0617100-1A patent/BRPI0617100A2/pt not_active IP Right Cessation
- 2006-08-31 WO PCT/JP2006/317691 patent/WO2007026950A1/en not_active Ceased
-
2008
- 2008-02-24 IL IL189697A patent/IL189697A0/en unknown
- 2008-03-31 NO NO20081572A patent/NO20081572L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| TW200745034A (en) | 2007-12-16 |
| NO20081572L (no) | 2008-03-31 |
| RU2008112290A (ru) | 2009-10-10 |
| IL189697A0 (en) | 2008-06-05 |
| JP5066516B2 (ja) | 2012-11-07 |
| KR20080049758A (ko) | 2008-06-04 |
| WO2007026950A1 (en) | 2007-03-08 |
| JP2009507758A (ja) | 2009-02-26 |
| EP1919919A1 (en) | 2008-05-14 |
| CN101268079B (zh) | 2011-09-14 |
| CN101268079A (zh) | 2008-09-17 |
| CA2620740A1 (en) | 2007-03-08 |
| AU2006285599A1 (en) | 2007-03-08 |
| US20090042856A1 (en) | 2009-02-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5066516B2 (ja) | 疼痛の治療に用いられるピリダジノン誘導体 | |
| ES2963417T3 (es) | Derivados de imidazol condensados como moduladores de IL-17 | |
| JP7041198B2 (ja) | Ｊａｋ阻害剤である５－クロロ－２－ジフルオロメトキシフェニルピラゾロピリミジン化合物 | |
| ES2436524T3 (es) | Derivados de pirazolo-quinazolina, procedimiento para su preparación y su uso como inhibidores de cinasas | |
| JP5213229B2 (ja) | キナーゼ調節因子および使用方法 | |
| ES2654288T3 (es) | Moduladores de P2X7 | |
| JP5116687B2 (ja) | がんおよび他の過剰増殖性疾患の処置のためのピロロ［２，１−ｆ］［１，２，４］トリアジン−４−イルアミンＩＧＦ−１Ｒキナーゼ阻害剤 | |
| AU2014400628B2 (en) | Aminopyridazinone compounds as protein kinase inhibitors | |
| RU2684641C1 (ru) | Производные пиразолопиридина в качестве модуляторов активности tnf | |
| ES2663622T3 (es) | Novedosas 1H-pirrolo[2,3-b]piridinas 3,4-disustituidas y 7H-pirrolo[2,3-c]piridacinas 4,5-disustituidas como inhibidores de LRRK2 | |
| BR112021002772A2 (pt) | compostos, composições farmacêuticas, método de tratamento de câncer, métodos para regular a atividade de uma proteína, para inibir a proliferação de uma população de células, para tratar um distúrbio, para preparar uma proteína, para inibir metástase de tumor e para tratamento de câncer e usos | |
| RU2679609C1 (ru) | Производные имидазопиридазина в качестве модуляторов активности tnf | |
| JP6890179B2 (ja) | 二環式アミド化合物及びその使用方法 | |
| CA3013618C (en) | Substituted pyrazolo[1,5-a]pyrimidine compounds as trk kinase inhibitors | |
| KR20190069529A (ko) | 유비퀴틴 특이적 프로테아제 7의 억제제로서 피페리딘 유도체 | |
| SK3842001A3 (en) | Pyrrolopyrimidines as protein kinase inhibitors (revised) | |
| EP3145512A1 (en) | Substituted ethynyl heterobicyclic compounds as tyrosine kinase inhibitors | |
| AU2022316995A1 (en) | Novel parp7 inhibitor and use thereof | |
| EA019647B1 (ru) | ПРОИЗВОДНЫЕ ТРИАЗОЛО[4,3-b]ПИРИДАЗИНА И ИХ ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ РАКА ПРЕДСТАТЕЛЬНОЙ ЖЕЛЕЗЫ | |
| US12398136B2 (en) | Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors | |
| CN104640865B (zh) | 作为激酶抑制剂的二氢吡咯烷子基-嘧啶 | |
| WO2016045598A1 (zh) | 4-取代吡咯并[2,3-d]嘧啶化合物及其用途 | |
| CN112584898A (zh) | P2x3受体拮抗剂 | |
| ES2603420T3 (es) | Derivados de 3,4-dihidropirrolo[1,2-a]pirazina-2,8(1H)-dicarboxamida, su preparación y uso terapéutico de los mismos | |
| CN114901640A (zh) | 适用于治疗血脂异常的新型化合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 5A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2161 DE 05/06/2012. |